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Abstract: Intrauterine progestins have many important current and potential gynecologic 
applications. This article describes the evidence for use of intrauterine progestin for common 
gynecologic conditions beyond its important role in contraception. The pharmacology of and 
selection criteria for use of the levonorgestrel intrauterine device is discussed, and the evidence 
for use of intrauterine progestin delivery for menorrhagia, endometriosis management, uterine 
fibroids, adenomyosis and endometrial hyperplasia is reviewed.
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Introduction
Progestins are available in a variety of formulations.1 Intrauterine delivery of progestin is 
an effective way to administer local treatment and bypass systemic side effects. Intrauterine 
drug delivery has the potential to treat many gynecologic conditions, but is under utilized 
because clinicians lack knowledge and skills and because the only current delivery system 
(Mirena®; Bayer HealthCare) is unavailable or costly in many countries.2
Progesterone is a key hormone in regulating the female reproductive system, 
  interacting at the level of the hypothalamus, the ovary, the uterus and the breast. 
  Progesterone exerts effects on ovulation, endometrial differentiation, cervical mucus, 
breast differentiation and uterine contractility.1,3 Progestins and their analogs and 
antagonists have many uses in gynecology including contraception, management of 
miscarriage, medical abortion and treatment of conditions related to endometrial and 
myometrial growth and development. Beyond providing highly effective contraception, 
intrauterine delivery is safe and effective in the management of menorrhagia, 
  dysmenorrhea, uterine myomata, and endometrial proliferation.4
We describe the evidence for use of intrauterine progestins for common gynecologic 
conditions in addition to their important role in contraception; we also review the 
evidence for use of intrauterine progestin delivery for menorrhagia, endometriosis 
management, uterine fibroids, endometrial hyperplasia and its concurrent use in women 
on hormone replacement therapy or tamoxifen.
Pharmacology
Many different progestins are used in oral and implantable contraceptives, however 
only one form of intrauterine delivery is currently approved for use by regulatory 
  agencies. The levonorgestrel intrauterine system (LNG-IUS, Mirena®) is a T-shaped 
device, with a reservoir containing 52 mg of levonorgestrel. In vivo, the hormone is International Journal of Women’s Health 2010:2 64
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released at an initial rate of 20 mcg daily, which progressively 
declines to half this rate by 5 years.1 Levonorgestrel is 
a 19-nortestosterone derivative and exhibits a profound 
  progestational effect on the endometrium.5 The endometrial 
lining becomes atrophic and inactive and cervical mucus 
becomes thick and scant.1 Approximately 80% of cycles 
are ovulatory.1
With the intrauterine system, levonorgestrel dose is 
concentrated in the endometrial cavity. The most frequently 
noted side effects, irregular bleeding and cramping, are due 
to the intrauterine location of the device and endometrial 
atrophy. A common concern with hormonal contraceptives is 
their effect on coagulation and thromboembolic events.1 With 
the LNG-IUS, serum levels are a fraction of the endometrial 
dose, and in the first 2 months following insertion have been 
measured in the pico gram range (86–760 pg).6 Large epi-
demiologic studies have not demonstrated an increased risk 
in clot formation with oral levonorgestrel at much higher 
serum concentrations.7
Patient selection is important factor in predicting success. 
Nulliparity is not a contraindication to placement.8 Ideally the 
uterus should sound between 6 and 9 cm. Uterine anomalies 
can compromise success by increasing expulsion rates and 
risk of perforation.1
Menorrhagia and the levonorgestrel 
intrauterine system
Menorrhagia is excessive blood loss with menstruation 
(greater than 80 mL blood loss or menses lasting longer 
than 7 days duration) and is a common gynecologic com-
plaint.9 The prevalence of menorrhagia increases through the 
  perimenopausal period. Menstrual disorders affect 10% to 
15% of women and are a common indication for hysterectomy 
in the US.9,10 One-third of women in the US undergo a hys-
terectomy, a rate much higher than in Western Europe.10 
This difference may be due in part to lower utilization of the 
LNG-IUS to control menorrhagia in the US, despite excel-
lent evidence that exists to support its use. Hysterectomy is a 
major surgery, and entails greater risks and costs than medical 
treatment. While hysterectomy remains a viable option for 
menorrhagia refractory to medical management, the LNG-IUS 
is underutilized to control menorrhagia.
The LNG-IUS has been evaluated for its impact on 
menstrual blood loss and acceptability as an alternative to 
hysterectomy.9,11–15 Menstrual blood loss with the LNG-IUS 
was reduced by 86% at 3 months, and 97% at 6 months, 
and parameters of anemia such as hematocrit and ferritin 
levels improved.13 The reduction in menorrhagia noted 
with the LNG-IUS is superior to that reported from all 
other forms of medical management, including use of 
oral contraceptives, tranexamic acid and prostaglandin 
synthetase inhibitors.10
The LNG-IUS has also been compared to a variety of 
ablative techniques. Endometrial ablation is a commonly 
used procedure in the surgical management of menorrhagia.16 
A range of techniques and devices are available for 
  endometrial ablation. The thermal balloon is a popular global 
ablation device that allows transcervical destruction of the 
endometrium.16 The LNG-IUS has been compared with 
thermal balloon ablation and manual hysteroscopic ablation 
for reduction of blood loss, patient satisfaction, and cost.16–18 
At 12 and 24 months of follow up, women treated with the 
LNG-IUS had significantly higher rates of amenorrhea than 
the ablation group (P = 0.025). A recent meta-analysis of 
6 randomized controlled trials comparing the LNG-IUS to 
endometrial ablation showed that outcomes, including quality 
of life measures, were comparable between the two methods 
at two years of follow up.19 Cost effectiveness analysis also 
supports the LNG-IUS as preferable in terms of direct and 
indirect costs to thermal balloon ablation.17
The acceptability for patients of a LNG-IUS in place of 
hysterectomy has been studied in women with menorrhagia. 
Women in Finland awaiting a scheduled hysterectomy for 
menorrhagia were randomized to either LNG-IUS insertion 
or to continue their current medical management.21 The 
primary outcome was the proportion of women cancelling 
hysterectomy at 6 months, which was the average wait 
time for a hysterectomy in Finland during the study period. 
At 6 months, 64% of women in the LNG-IUS group had 
decided against hysterectomy as compared to 14% of the 
control group (P  0.001).20 Five-year follow up of women 
  randomized to LNG-IUS or hysterectomy showed equal 
satisfaction with treatment outcomes in both groups, but 
lower costs in the LNG-IUS group.21
Endometriosis and the 
levonorgestrel intrauterine system
Endometriosis, the presence of endometrial cells outside of 
the uterus, is the most common diagnosis among chronic 
pelvic pain patients, and affects 7% to 20% of all women.5 In 
addition to chronic pelvic pain, endometriosis is associated 
with infertility.5,22 Therapy for endometriosis is both medical 
and surgical. Surgical ablation of implants as well as use of 
medical therapies such as non steroidal anti-inflammatory 
drugs, progestins like depot medroxyprogesterone acetate, 
continuous oral contraceptives, gonadotropin releasing International Journal of Women’s Health 2010:2 65
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  hormone analogs (GnRHa) to induce a pseudo menopause, 
and androgen derivatives are the mainstays of treatment.5 The 
medications that elicit the most profound improvement have 
systemic side effects such as estrogen deprivation, which 
limit the duration of their use.
The role of the LNG-IUS in management of this common 
and debilitating disorder has been evaluated by multiple 
  studies.5,23–25 A pilot study examined the role of LNG-IUS as a 
postoperative adjunct to surgical ablation for endometriosis.26 
When compared with expectant management, the LNG-IUS 
recipients had a reduced rate of recurrence of pelvic pain (2/20 
compared with 9/20) and an increased rate of satisfaction 
(15/20 compared with 10/20).26 Similarly, a randomized 
controlled trial comparing LNG-IUS to medical therapy 
with a GnRHa had promising results.25 Eighty-two women 
with surgically confirmed endometriosis were randomized to 
LNG-IUS or GnRHa and, using visual analog scores (VAS), 
pain and bleeding patterns were assessed at baseline and at 
6-month intervals. At 36 months, 59% of women were still 
using the LNG-IUS and 82% of these users reported a lower 
VAS score compared with GnRHa.23
A  prospective  study  followed  34  women  with 
  laparoscopically confirmed early stage endometriosis who 
had an LNG-IUS placed at time of surgery.27 Patients were 
followed for 3 years and continuation rates, pain scores 
and bleeding rates were assessed at regular intervals and 
  compared to baseline levels.27 Significant improvements in 
all parameters were noted at 12 months, with an improvement 
in pain (recorded by visual analog score) from 7.7 at baseline 
to 3.5 at 12 months and 2.7 at 36 months (P  0.02).27 While 
this study’s findings are limited by its lack of controls, small 
cohort and high discontinuation rate (32% at 12 months, 
most commonly for irregular bleeding), it shows promise 
and further research should be conducted.
The LNG-IUS offers several advantages for control of 
pelvic pain associated with endometriosis including effective 
  contraception, minimal systemic effects and up to 5 years 
of benefit, as compared with 6 months typical of GnRHa 
  treatment.
Uterine fibroids and the 
levonorgestrel intrauterine system
Uterine leiomyomas and their clinical sequelae are a common 
gynecologic problem, as fibroids are present in approximately 
25% of reproductive aged women.28 While leiomyomas may 
be asymptomatic, they can be associated with heavy menstrual 
bleeding, dysmenorrhea, pelvic pressure, and obstructive 
symptoms such as urinary frequency and constipation.29 
Symptoms from leiomyomas may be managed with medical 
therapy, but they remain the most common indication for 
hysterectomy in the US.29 The uterine location of the myomas 
– subserosal, intramural or submucosal – effects the clinical 
sequelae. Subserosal locations are more commonly associated 
with obstructive symptoms, while submucosal are correlated 
with heavy menstrual bleeding.
The LNG-IUS has been studied in women with 
  leiomyomas, specifically in relation to acquired menor-
rhagia, uterine volume, and expulsion rates.29–31 Fewer 
studies have assessed relief of obstructive symptoms or 
dysmenorrhea.
The beneficial effect of the LNG-IUS on acquired 
  menorrhagia due to a leiomyomatous uterus is well 
  established. In prospective trials, the LNG-IUS has 
  significantly decreased menorrhagia from fibroids, as 
  measured by pictorial blood loss assessment, hemoglobin 
levels, and blood loss calenders.28,30,32–36
Intrauterine progestin has been compared to ablation 
in the treatment of menorrhagia in patients with at least 
one myoma.34 A cohort of women with menorrhagia and 
a leiomyomatous uterus (380 g) who declined surgery, 
were treated with an LNG-IUS. Patients were evaluated at 3, 
6 and 12 months and compared to historical controls treated 
with thermal balloon ablation.34 At 3 months, blood loss 
was significantly less in the ablation group (P  0.0001). 
By 6 months, however, there was no statistically significant 
difference in hemoglobin values, pictorial blood loss score 
or uterine volume between the two groups. These findings 
persisted at the 12-month examination.34
Not all women with myomas are successfully treated 
with the LNG-IUS, perhaps because response is deter-
mined by the fibroids’ uterine location. In an attempt to 
identify factors predictive of non response to the LNG-IUS, 
44 women presenting for hysterectomy after failed LNG-
IUS management for menorrhagia were studied.37 Persistent 
  menorrhagia was the indication for the majority (44 out of 50). 
Women were retrospectively identified and their pathology 
reviewed. Examination of the histology demonstrated that 
the majority of women who failed therapy with an LNG-IUS 
and fibroids had an abnormal uterus.37 Uterine malformations, 
such as submucosal fibroids, was the most common finding, 
although a unicornuate uterus and an LNG-IUS embedded 
in an old cesarean scar were also noted.38 These specimens 
showed the expected atrophy, but also contained some areas 
of persistent endometrial shedding deemed to be consistent 
with incomplete endometrial suppression.37 Durations of 
exposure to the LNG-IUS were not specified in the report of International Journal of Women’s Health 2010:2 66
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this study, which is a chief limitation in assessing the impact 
of the LNG-IUS.
Studies have evaluated the effect of LNG-IUS on 
  leiomyoma size, but findings have not been consistent. 
Using sonographic measurements, Grigorieva et al found a 
  significantly decreased uterine volume in LNG-IUS users 
starting at 3 months after placement and persisting through 
12 months.30 They also found a significant decrease in 
  leiomyoma size from 6 months to 12 months of use (30–19 mL, 
P = 0.01). A study comparing the effect of LNG-IUS on 
menorrhagia in women with fibroids and contraceptive users 
without fibroids also showed a significant decrease in uterine 
volume over time and between groups.38
Evidence of the outcomes of intrauterine progestin on 
fibroids comes indirectly from a trial comparing women with 
a history of breast cancer and receiving tamoxifen. These 
patients were randomized to endometrial surveillance alone, 
or insertion of LNG-IUS for prophylaxis of endometrial 
hyperplasia.39 Sonographic uterine measurements showed 
that women with the LNG-IUS had decreased endometrial 
  thickness, uterine anterior posterior diameter, uterine cavity 
length and long diameter. At 1 year of use, endometrial 
thickness and myoma volume were significantly decreased 
(P = 0.04).40 A trend towards decrease in size of submucosal 
fibroids in the LNG-IUS users and a significant increase in 
the development of fibroids in the control group were also 
noted.
A 2009 Turkish prospective cohort study assessed the 
impact of the LNG-IUS on uterine and ovarian volume. At 
one year of use, endometrial thickness and myoma volume 
were significantly decreased (P = 0.04).31,40
In contrast, other studies have not shown a significant 
decrease in uterine volume with an LNG-IUS, despite a 
  consistently significant decrease in blood loss scores.34,41 
These conflicting findings probably reflect study design, 
  specifically length of follow up and inclusion and exclusion 
criteria. However, it has also been suggested that progesterone 
may have both stimulatory as well as inhibitory effects on 
myometrial cells.37 Further research is needed to elucidate 
the role intrauterine delivery of progestin analogues may 
play in leiomyoma volume. For the well-counseled patient 
with menorrhagia secondary to uterine leiomyomas, a trial 
of the LNG-IUS is supported by the evidence.
Endometrial hyperplasia and the 
levonorgestrel intrauterine system
Given the profound endometrial atrophy the LNG-IUS 
induces, its potential for management of endometrial 
  hyperplasia has been investigated.42–44 Endometrial 
  hyperplasia ranges from simple to complex, with or without 
atypia and is considered a precursor of endometrial cancer.44 
In the presence of atypia, risk of progression to cancer is 
estimated at 30%, thus the standard of care in women who 
have completed childbearing is hysterectomy for hyperplasia 
with atypia.45 For women who wish to preserve fertility, or 
who have hyperplasia without atypia, or are poor surgical 
candidates, oral or depot progestin therapy is typical.43,45 
Controversy exists about the appropriate length of time of 
treatment and the dosage of oral therapy.
Treatment response to oral and intrauterine pro-
gestins has been compared in groups with endometrial 
complex hyperplasia with atypia and well differentiated 
  carcinoma.45 Both groups responded well to therapy with 
no statistical difference between therapy route when meno-
pausal status was controlled for. For women with complex 
atypical hyperplasia, 67% had complete resolution, 11% 
regressed to complex hyperplasia without atypia, and 22% 
had persistent disease over 11 months.46 For women with 
well differentiated carcinoma, 42% completely resolved 
and 58% had persistent disease over a 12-month period.45 
Of note, no patients with persistent atypia on biopsy at 
7 months ultimately regressed or resolved. While a small 
sample size precludes definitive conclusions, this study 
suggests that minimal benefit is obtained for continuing 
to treat patients with atypia on biopsy with more than 
7 months of medical therapy and no significant difference 
in efficacy exists between oral and intrauterine therapy. 
The LNG-IUS has been contrasted with standard oral 
therapy and found to equal or surpass it.43,46,47 Orbo 
et al, report a prospective trial contrasting low dose oral 
  progestin therapy with LNG-IUS. A total of 258 women 
with endometrial hyperplasia were randomized to either 
intrauterine or oral treatment. The D score classification 
was used to characterize histological findings consistent 
with risk for progression. At 6 months of follow up, 
patients in the LNG-IUS arm had significantly higher rates 
of regression.46 Long-term follow up occurring at 58 to 
106 months was notable for higher rates of regression in 
those with intrauterine treatment.46
In observational studies of women with hyperplasia (both 
with and without atypia) regression was achieved by the major-
ity receiving LNG-IUS treatment.43,44,50 The largest study, by 
Varma et al, was a prospective observation of 105 women with 
endometrial hyperplasia.48 Women were included in the study 
if they had non atypical hyperplasia and selected an LNG-IUS 
over oral therapy. Women with atypical hyperplasia were only International Journal of Women’s Health 2010:2 67
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included in the study if they were not surgical candidates.43 
Their hyperplasia was regularly assessed by endometrial 
biopsy with the LNG-IUS in place. A 90% regression of 
hyperplasia was noted by 24 months (94/105 patients).43
Tamoxifen and the levonorgestrel 
intrauterine system
Tamoxifen is the adjuvant therapy of choice for patients with 
estrogen receptor positive breast tumors.49 Tamoxifen has a 
proliferative effect on the postmenopausal endometrium, 
resulting in a higher incidence of endometrial pathology.49,50 
The increased risk of developing endometrial cancer for a 
woman on tamoxifen is 2 to 3 times that of an age-matched 
control.51 Management of the asymptomatic, postmenopausal 
patient on tamoxifen is controversial.51
A randomized, controlled trial evaluated the impact of 
a prophylactic LNG-IUS compared with observation in 
women undergoing tamoxifen therapy after breast cancer 
surgery. One hundred and thirteen women were enrolled and 
  followed for 12 months. Comparison of endometrial biopsies 
at 12 months revealed that the LNG-IUS patients had a much 
lower relative risk for formation of endometrial polyps (0.12, 
confidence interval 0.02–0.91).52 The LNG-IUS was a well 
accepted intervention, with 95% retention at 1 year.52
In another study, 142 postmenopausal women on tamoxifen 
after breast cancer treatment were randomized to either the 
LNG-IUS or observation and followed with endometrial 
biopsies and blood draws for 3 years. Of this group, 70 had an 
LNG-IUS and 72 had observation during standard tamoxifen 
therapy. Six were excluded from analysis due to inability to 
insert the device. At 36 months of follow up there were no 
statistically significant differences between the two groups in 
serum lipid profiles, but a significant difference in endometrial 
pathology was seen at follow up biopsy. In the control group, 
endometrial polyps were found in 14 patients and endometrial 
hyperplasia in 4. Among the women treated with an LNG-IUS, 
4 had polyps but none had hyperplasia (P  0.05).50
These long-term results from two small trials show 
  promise for the LNG-IUS as a means of reducing endometrial 
pathology associated with tamoxifen.
Conclusion
Progestin plays a critical role in gynecologic treatments 
beyond their current use in contraception. Intrauterine deliv-
ery is an effective localized therapy, and intrauterine progestin 
has many important applications in managing gynecologic 
conditions such as menorrhagia, endometriosis, leiomyomas 
and endometrial hyperplasia.
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